D-1058-2017 Class III Terminated

Recalled by Teva Pharmaceuticals USA — North Wales, PA

FDA drug recall D-1058-2017 was initiated by Teva Pharmaceuticals USA on Aug 2, 2017 and is designated Class III. Reason for recall: Failed Moisture Limits: out of specification test results for water content obtained during stability testing. The recall status is terminated (terminated Feb 28, 2018). Affected quantity: 2,880 cartons (30 unit dose blister pack per carton).

Recall details

Product Type
Drugs
Report Date
Aug 16, 2017
Initiation Date
Aug 2, 2017
Termination Date
Feb 28, 2018
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
2,880 cartons (30 unit dose blister pack per carton)

Product description

Glipizide Extended-Release Tablets (anti-diabetic agent), 5 mg, packaged in 30-unit dose blister pack per carton, Rx only, Mfd for: Watson Laboratories, Inc., Corona, CA 92880, Mfd by: Patheon Pharmaceuticals, Inc., Cincinnati, OH 43215, NDC 0591-0844-15

Reason for recall

Failed Moisture Limits: out of specification test results for water content obtained during stability testing.

Distribution pattern

Product distributed to OH, IL, PA, MI, VA and CT

Code information

Lot # 3138405A, Exp 8/2017

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1058-2017
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1058-2017. Report a data issue: hello@regdatalab.com.